GlassScriptPhysician profile
Christy B Masterman
NPI 1841396413
$5,301.20
in general payments reported to CMS, 2019-2025
21 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2022: $943 · 2023: $1,191 · 2024: $1,393 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.34 |
| Education | $279.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,570.00 | 2021-2025 | Tremfya |
| Abbvie INC. | $893.01 | 2021-2025 | |
| Merz North America, INC. | $614.48 | 2022-2025 | |
| Lilly USA, LLC | $515.13 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $294.32 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $181.01 | 2021-2025 | |
| Ucb, INC. | $154.00 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $131.73 | 2021-2025 | |
| Dermavant Sciences, INC. | $130.46 | 2023-2024 | Vtama |
| Incyte Corporation | $119.28 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $118.22 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $107.12 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $92.78 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $74.83 | 2022-2024 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.21 | 2022-2024 | |
| Organogenesis INC. | $44.64 | 2024 | |
| Allergan, INC. | $43.26 | 2021-2022 | |
| Organon LLC | $20.90 | 2025 | Vtama |
| Amgen INC. | $19.50 | 2023 | Otezla |
| Vyne Pharmaceuticals INC. | $18.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Masterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.